A new breed of Laboratory Information Management System (LIMS), which features a breakthrough user interface, is being launched by London-based start-up company, Two Fold Software Limited.
Precision Antibody announced its selection by Science Applications International Corporation–Frederick to provide antibody and antigen characterization, including surface plasmon resonance analysis, for the National Cancer Institute’s CPTC initiative.
Lampire Biological Laboratories announced that it signed an agreement with Proliant Health and Biologicals to do contract filling & provide BSA to customers requiring less than Proliant’s standard 10 kilogram packaging.
Eighty years ago, the medical establishment believed cancer was caused by a dysfunction of metabolism, but the idea went out of vogue. Now, scientists are again looking at metabolism and its role in cancer and other common diseases.
Studying a protein already known to play an important role in type 2 diabetes and cancer, genomics researchers have discovered that it may have an even broader role in disease, particularly in other metabolic disorders and heart disease.
Tarsa Therapeutics, Inc. has completed patient enrollment in the multinational, randomized, double-blind, placebo-controlled Phase 3 ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis.
Data from the VERxVE study show that an investigational, once-daily extended-release formulation of nevirapine was non-inferior to twice-daily immediate release Viramune (nevirapine) tablets in treatment-naïve HIV-1 patients.
Pharmacy benefits manager Medco Health Solutions Inc. said its net income rose 14 percent in the second quarter as it did more business with its newest clients and drug prices increased.
Drugmaker Bristol-Myers Squibb Co. said its second-quarter sales were up slightly but profit was down nearly 6 percent, due to the loss of income from its former nutrition business, spun off late last year.
Biotechnology company Genzyme Corp. said its profit shrank drastically in the second quarter because of falling sales and charges partly connected to its manufacturing problems.
Pharmaceuticals maker Roche Holding AG posted a 37 percent rise in six-month net profit on strong drug sales and lower costs related to its takeover of U.S.-based Genentech.
Eli Lilly and Co. said its second-quarter net income soared 16%, boosted in part by revenue growth from key drugs that face patent expirations in the coming years.
Federal health officials are barring new patients from enrolling in a safety study of GlaxoSmithKline's controversial diabetes pill Avandia, a week after a panel of experts ruled that the drug increases heart risks.
A dozen recent federal inspections of a Johnson & Johnson factory for heartburn and other nonprescription medicines show a host of violations that could affect the quality and makeup of the drugs.
In an effort to better serve its readers, Drug Discovery & Development has enhanced its e-newsletter distribution system. To ensure that you continue to receive prompt delivery of DDD Update, please update your spam filters and add mail.dddmag.com to your safe sender list.